The third quarter of 2025 saw 62 biopharma layoff rounds, closely mirroring previous quarterly figures and positioning 2025 to exceed 2024’s total workforce reductions. Major companies such as Novo Nordisk and Merck announced substantial cuts as part of cost-saving and pipeline refocusing measures, underscoring ongoing sector pressures amid regulatory and market uncertainties.